Maze Finds A Way As Shionogi Signs On To Develop Pompe Drug

Months after an antitrust lawsuit challenged its deal with Sanofi and raised uncertainty about the future of MZE001, Maze secured a new partner for potentially the first oral Pompe disease drug.